Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Cello Health makes strong start to the year; in track to meet expectations

The strategic marketing group has seen revenues, profits and margins advance

Cello Health plc (LON:CLL) said trading in the first six months of the year had been strong, adding it expects results for the year to be in line with market forecasts.

The healthcare-focused advisory group said it saw “good growth” in revenues and earnings, while profit margins were slightly higher than the comparable period last year.

READ: Cello Health confident of "achieving a successful result in 2018" after strong start to year

The Cello Health division had a “robust” first-half, with "excellent" like-for-like gross profit growth, investors were told.

Cello Signal was described as having had a “solid” start to the year. The company said while gross profit had declined slightly year-on-year, but margins have increased, meaning operating profits will expand slightly.

The businesses acquired last year are now fully absorbed into Cello and “continue to make a good contribution”, the company said.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK